Drug News
Women More Often Treated with Low-Dose Dabigatran
Despite trend toward lower stroke risk with high dose
Your search for dabigatran returned 11 results
Drug News
ESC: Complications Noted After Dabigatran Heart Valve Tx
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
News
Stroke, Major Bleed Risk Compared Among Novel Oral Anticoagulants
The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
News
Impact of Oral Anticoagulants on Renal Outcomes Compared
Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Drugs in the Pipeline
Pradaxa Under Review for DVT and PE
The FDA has accepted for review the sNDA for Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim) in patients with deep vein thrombosis (DVT) and pulmonary embolism (PE).
News
Dosing Errors Common with Certain Blood-Thinning Medications
Study of newer medications finds 16 percent receive too much or too little
News
Pradaxa 150mg available for stroke risk reduction
Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010.
News
GI Bleed Hospitalization Risk Linked to Oral Anticoagulant Choice, PPI Cotherapy
To compare the incidence of hospitalization for upper GI tract bleeding, researchers used US Medicare beneficiary files to identify a cohort of patients that were ≥30 years old who initiated oral anticoagulation therapy with apixaban, dabigatran, rivaroxaban, or warfarin, with or without PPI cotherapy.
Safety Alerts and Recalls, Uncategorized
Single Lot of Pradaxa 75mg Recalled
Boehringer Ingelheim announced that it is conducting a nationwide recall of a single manufacturing lot of Pradaxa (dabigatran etexilate mesylate) capsules 75mg.
Drugs in the Pipeline
FDA Accepts sNDA for New Pradaxa Indication
Boehringer Ingelheim announced that the FDA has accepted for filing the supplemental New Drug Application (sNDA) for Pradaxa (dabigatran etexilate mesylate) for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have had primary elective total hip replacement surgery.
